Hologic, Inc.
HOLX
Market Cap$14.43B
Close$
Earnings Call Q2 2023
May 1, 2023 - AI Summary
Hologic reported strong financial results for the second quarter of fiscal 2023, with total revenue of $1.03 billion and non-GAAP earnings per share of $1.06, both exceeding expectations.
The company's organic revenue, excluding COVID, grew 21.9%, driven by strong performance in Diagnostics (14.9% growth), Surgical (25.2% growth), and Breast Health (25.7% growth).
Hologic reaffirmed its guidance for low double-digit organic revenue growth for each division in fiscal 2023, excluding COVID. However, they acknowledged that tougher comps in the third quarter may impact future growth rates.
Exclusive for Stockcircle Pro members
Sign up
$173.86
168.5% upside
Current Fair Value
168.5% upsideUndervalued by 168.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.43 Billion |
|---|---|
| Enterprise Value | $13.27 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $3.35 |
| Beta | 0.55 |
| Outstanding Shares | 225,774,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 26.26 |
|---|---|
| PEG | -23.82 |
| Price to Sales | 3.81 |
| Price to Book Ratio | 3.24 |
| Enterprise Value to Revenue | 3.3 |
| Enterprise Value to EBIT | 22.33 |
| Enterprise Value to Net Income | 23 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Hologic, Inc.
6,478 employees
CEO: Stephen MacMillan Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment.